$CSX

ZILLMER JOHN J sold $464K of CSX

ZILLMER JOHN J sold 10,000 shares of CSX CORP (CSX) at $46.45 ($0.46M total) on 2026-06-03.

Original reporting
SEC EDGAR · ZILLMER JOHN J
Published Jun 4, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CSX
Neutral
medium confidence
Mentioned
$CSX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSXNeutralLow
01

Why it matters

The disclosure provides a new datapoint on insider behavior but does not include earnings, guidance, or legal/contract developments that would typically reset valuation.

02

Market read

Traders may monitor follow-on insider activity, but the filing alone is unlikely to be a standalone catalyst.

03

What to watch

Form 4 details don’t reveal reasons for the sale, tax planning, or diversification needs; also, single-director transactions can be noisy versus company-wide insider trends.

Relevance 6/10Novelty 3/10Timing: Filed after-hours (2026-06-04 16:15 ET) for a sale executed 2026-06-03.

Background

This is an SEC Form 4 insider transaction disclosure (director open-market sale) for CSX.

Company-level read

Ticker impact

$CSXNeutralMedium confidence
Context

Director Zillmer sold 10,000 CSX shares in an open-market transaction disclosed via SEC Form 4 on 2026-06-03.

Expected impact

Low near-term impact; any effect is likely limited to intraday sentiment/positioning rather than a fundamental re-rate.

Evidence & confidence

The filing is an ownership-change disclosure with no accompanying operational/financial catalyst; size is meaningful but not clearly indicative of a major corporate event.

Market effects

Rail/transport sentiment could see minor read-through from insider activity, but no sector-wide catalyst is provided.

None indicated; this is company-specific insider activity.

None indicated; no cross-border or macro linkage mentioned.

Counterpoint

The sale may be routine liquidity/portfolio rebalancing (no 10b5-1 plan cited), so it may not reflect negative expectations.

Key entities

  • CSX CORP

    Subject of the insider transaction disclosure; director sold 10,000 shares at $46.45 on 2026-06-03.

  • ZILLMER JOHN J

    Director who executed the open-market sale; holdings after transaction: 353,714 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NSCMedAI 8/10

Rail Merger Faces More Headwinds As Port Of Mobile Objects

The $85B merger between Union Pacific (UNP) and Norfolk Southern (NSC) faces delays and opposition. The Port of Mobile, citing potential economic harm, plans to submit comments. Rival railroads (BNSF, CSX, CPKC) object to repeated data corrections in the merger proposal, calling for a halt to further changes.

$CSXMed

BNSF, CPKC, and CSX to request broad access to a combined UP

BNSF, CPKC, and CSX plan to request extensive trackage rights over a combined Union Pacific-Norfolk Southern system, if regulators approve their $85 billion merger. The railroads argue the merger will harm competition and the economy. BNSF seeks 824 miles of trackage rights between Chicago and Pennsylvania, while CPKC targets the Kansas City-St. Louis corridor and other routes. CSX also aims for access to the Kansas City-St. Louis trackage.

$CSXMed

CSX (CSX) Earnings Beat Leaves Its Valuation Question Open

CSX reported Q2 FY2026 earnings exceeding Wall Street estimates, with revenue and adjusted EPS above expectations. Shares have seen a 90-day return of 4.88% and a YTD return of 36.23%. The stock's fair value is estimated at $52.85, slightly above its last close of $49.41, with a P/E ratio of 28.4x, leaving valuation debates open.

$AAPLHighAI 8/10

Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today?

Apple (AAPL), Q32 Bio (QTTB), and CSX Corp. (CSX) reached 52-week highs. AAPL rose 0.6% to $323.45; Citi raised its target to $365. QTTB surged 90% after positive clinical data; Wells Fargo upgraded it to 'Overweight' with a $66 target. CSX gained 0.4% to $49.90; Raymond James lifted its target to $56. Year-to-date gains: AAPL +16%, CSX +36%, QTTB +543%.

$CSXMedAI 8/10

Bank of America Securities Remains a Buy on CSX (CSX)

Bank of America Securities maintained a Buy rating on CSX with a $56 price target. Wells Fargo also recommended Buy, while Bernstein advised Hold. CSX reported Q2 revenue of $3.94B and net profit of $1B, up from last year. Insider sentiment is negative, with increased selling activity.